DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

John B Buse, Bruce H R Wolffenbuttel, William H Herman, Natalie K Shemonsky, Honghua H Jiang, Jessie L Fahrbach, Jamie L Scism-Bacon, Sherry A Martin, John B Buse, Bruce H R Wolffenbuttel, William H Herman, Natalie K Shemonsky, Honghua H Jiang, Jessie L Fahrbach, Jamie L Scism-Bacon, Sherry A Martin

Abstract

Objective: To compare the ability of two starter insulin regimens to achieve glycemic control in a large, ethnically diverse population with type 2 diabetes.

Research design and methods: During the initiation phase of the DURABLE trial, patients were randomized to a twice-daily lispro mix 75/25 (LM75/25; 75% lispro protamine suspension, 25% lispro) (n = 1,045) or daily glargine (GL) (n = 1,046) with continuation of prestudy oral antihyperglycemic drugs.

Results: Baseline A1C was similar (LM75/25: 9.1 +/- 1.3%; GL: 9.0 +/- 1.2%; P = 0.414). At 24 weeks, LM75/25 patients had lower A1C than GL patients (7.2 +/- 1.1 vs. 7.3 +/- 1.1%, P = 0.005), greater A1C reduction (-1.8 +/- 1.3 vs. -1.7 +/- 1.3%, P = 0.005), and higher percentage reaching A1C target <7.0% (47.5 vs. 40.3%, P < 0.001). LM75/25 was associated with higher insulin dose (0.47 +/- 0.23 vs. 0.40 +/- 0.23 units x kg(-1) x day(-1), P < 0.001) and more weight gain (3.6 +/- 4.0 vs. 2.5 +/- 4.0 kg, P < 0.0001). LM75/25 patients had a higher overall hypoglycemia rate than GL patients (28.0 +/- 41.6 vs. 23.1 +/- 40.7 episodes x pt(-1) x year(-1), P = 0.007) but lower nocturnal hypoglycemia rate (8.9 +/- 19.3 vs. 11.4 +/- 25.3 episodes x pt(-1) x year(-1), P = 0.009). Severe hypoglycemia rates were low in both groups (LM75/25: 0.10 +/- 1.6 vs. GL: 0.03 +/- 0.3 episodes x pt(-1) x year(-1), P = 0.167).

Conclusions: Compared with GL, LM75/25 resulted in slightly lower A1C at 24 weeks and a moderately higher percentage reaching A1C target <7.0%. Patients receiving LM75/25 experienced more weight gain and higher rates of overall hypoglycemia but lower rates of nocturnal hypoglycemia. Durability of regimens will be evaluated in the following 2-year maintenance phase.

Trial registration: ClinicalTrials.gov NCT00279201.

Figures

Figure 1
Figure 1
Flow of patients through the initiation phase (first 24 weeks) of the DURABLE trial.
Figure 2
Figure 2
A: Change in A1C from baseline to end point for patients treated with LM75/25 (■) versus glargine (□). **P < 0.01. B: A1C values at each visit for patients treated with LM75/25 (▲) versus glargine (□). **P < 0.01; †P < 0.001. C: Percent of patients achieving A1C target <7.0% at end point for patients treated with LM75/25 (■) versus glargine (□). †P < 0.001. D: Observed mean overall hypoglycemia rate (episodes · pt−1 · year−1) and TDI dose (units/kg) at each visit between 6 and 24 weeks of therapy for patients treated with LM75/25 (▲, hypoglycemia rate; △, TDI) or glargine (■, hypoglycemia rate; □, TDI).

References

    1. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P: Comparison of insulin regimens in patients with non-insulin–dependent diabetes mellitus. N Engl J Med 1992; 327: 1426– 1433
    1. UK Prospective Diabetes Study Group (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837– 853
    1. Rosenstock J, Schwartz SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631– 636
    1. Riddle MC, Rosenstock J, Gerich J: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080– 3086
    1. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254– 259
    1. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B: Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374– 381
    1. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH: Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034– 2044
    1. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: the INITIATE Study Group Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260– 265
    1. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: the 4-T Study Group Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716– 1730
    1. Fahrbach J, Jacober S, Jiang H, Martin S: The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2: 831– 838
    1. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925– 926
    1. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Jr, Buse JB: A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 2005; 23: 78– 86
    1. Fritsche A, Schweitzer MA, Haring HU: the 4001 Study Group Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003; 138: 952– 959
    1. American Diabetes Association Workgroup on Hypoglycemia Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245– 1249
    1. American Diabetes Association Standards of medical care in diabetes—2009 (Position Statement). Diabetes Care 2009; 32( Suppl. 1): S13– S61
    1. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926– 931
    1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F: AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the managementof diabetes mellitus. Endocr Pract 2007; 13( Suppl. 1): 1– 68
    1. Gerich JE: Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306– 1316
    1. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107– 2114
    1. American Diabetes Association Consensus statement: postprandial blood glucose. Diabetes Care 2001; 24: 775– 778
    1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545– 2559
    1. The ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560– 2572
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193– 203
    1. National Committee for Quality Assurance. [Accessed 20 January 2009];Diabetes physician recognition program. Available from .

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться